{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:21:32Z","timestamp":1792606892523,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.cll.2026.02.011","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:11:31Z","timestamp":1775041891000},"page":"259-277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Updates on Use and Monitoring of Direct Thrombin Inhibitors"],"prefix":"10.1016","volume":"46","author":[{"given":"Amir","family":"Navaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Kostousov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Teruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"207","key":"10.1016\/j.cll.2026.02.011_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-3-642-23056-1_3","article-title":"The anticoagulant and antithrombotic mechanisms of heparin","author":"Gray","year":"2012","journal-title":"Handb Exp Pharmacol"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib2","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood.V83.3.677.677","article-title":"A novel nucleotide-based thrombin inhibitor inhibits clot-bound thrombin and reduces arterial platelet thrombus formation","volume":"83","author":"Li","year":"1994","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1055\/s-0030-1267849","article-title":"Anticoagulation management","volume":"27","author":"Cook","year":"2010","journal-title":"Semin Interv Radiol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib4","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.thromres.2006.10.026","article-title":"The anti-inflammatory effects of heparin and related compounds","volume":"122","author":"Young","year":"2008","journal-title":"Thromb Res"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5492\/wjccm.v8.i6.87","article-title":"Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation","volume":"8","author":"Burstein","year":"2019","journal-title":"World J Crit Care Med"},{"issue":"5","key":"10.1016\/j.cll.2026.02.011_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1517\/13543784.9.5.1119","article-title":"Bivalirudin: a new generation antithrombotic drug","volume":"9","author":"Scatena","year":"2000","journal-title":"Expet Opin Invest Drugs"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib7","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1517\/17425255.3.4.609","article-title":"Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology","volume":"3","author":"Ahrens","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib8","first-page":"60","article-title":"Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures","volume":"22","author":"Chew","year":"2002","journal-title":"H\u00e4mostaseologie"},{"issue":"15","key":"10.1016\/j.cll.2026.02.011_bib9","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1016\/S0021-9258(18)81848-8","article-title":"Anticoagulant activity of synthetic hirudin peptides","volume":"264","author":"Maraganore","year":"1989","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/0014-5793(84)80165-9","article-title":"The complete amino acid sequence of hirudin, a thrombin specific inhibitor. Application of colour carboxymethylation","volume":"165","author":"Dodt","year":"1984","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.cll.2026.02.011_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/02676591231221708","article-title":"Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery","volume":"40","author":"Meshulami","year":"2025","journal-title":"Perfusion"},{"key":"10.1016\/j.cll.2026.02.011_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1237601","article-title":"Is it time to switch to bivalirudin for ECMO anticoagulation?","volume":"10","author":"Navaei","year":"2023","journal-title":"Front Med"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib13","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1161\/01.CIR.89.4.1523","article-title":"Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4","volume":"89","author":"Eitzman","year":"1994","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCINTERVENTIONS.110.959098","article-title":"Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention","volume":"4","author":"Kimmelstiel","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/01.CIR.97.3.251","article-title":"Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor","volume":"97","author":"Xiao","year":"1998","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.cll.2026.02.011_bib16","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1538-7836.2007.02623.x","article-title":"Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis","volume":"5","author":"Young","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"9","key":"10.1016\/j.cll.2026.02.011_bib17","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/jth.13057","article-title":"UNBLOCK: an open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis","volume":"13","author":"O'Brien","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib18","first-page":"408","article-title":"Bivalirudin as an alternative to heparin for anticoagulation in infants and children","volume":"20","author":"Buck","year":"2015","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.cll.2026.02.011_bib19","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2024.07.045","article-title":"Bivalirudin vs heparin anticoagulation in STEMI: confirmation of the BRIGHT-4 results","volume":"84","author":"Stone","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib20","first-page":"492","article-title":"Bivalirudin versus heparin monotherapy in non-ST-segment elevation myocardial infarction","volume":"8","author":"Erlinge","year":"2019","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"12","key":"10.1016\/j.cll.2026.02.011_bib21","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1016\/j.jtha.2023.08.013","article-title":"Defining heparin resistance: communication from the ISTH SSC subcommittee of perioperative and critical care thrombosis and hemostasis","volume":"21","author":"Levy","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jtha.2024.01.001","article-title":"Finding a common definition of heparin resistance in adult cardiac surgery: communication from the ISTH SSC subcommittee on perioperative and critical care thrombosis and hemostasis","volume":"22","author":"Levy","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jointm.2023.04.001","article-title":"Effectiveness and safety of therapeutic plasma exchange to modify the functionality of heparin-induced thrombocytopenia antibodies and correct profound thrombocytopenia: a case report and literature review","volume":"3","author":"Graser","year":"2023","journal-title":"J Intensive Med"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib24","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3390\/jcm12030786","article-title":"How to solve the conundrum of heparin-induced thrombocytopenia during cardiopulmonary bypass","volume":"12","author":"Revelly","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.cll.2026.02.011_bib25","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1310\/hpj5111-922","article-title":"Direct thrombin inhibitor resistance and possible mechanisms","volume":"51","author":"Cardinale","year":"2016","journal-title":"Hosp Pharm"},{"issue":"1","key":"10.1016\/j.cll.2026.02.011_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-232262","article-title":"Bivalirudin resistance in a patient on veno-venous extracorporeal membrane oxygenation with a therapeutic response to argatroban","volume":"13","author":"Berlioz","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1182\/blood-2003-07-2229","article-title":"Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin","volume":"103","author":"Eichler","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cll.2026.02.011_bib28","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s13054-014-0504-2","article-title":"Heparin-like effect in postcardiotomy extracorporeal membrane oxygenation patients","volume":"18","author":"Ranucci","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cll.2026.02.011_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2019.12.007","article-title":"Monitoring bivalirudin therapy in children on extracorporeal circulatory support devices: thromboelastometry versus routine coagulation testing","volume":"186","author":"Teruya","year":"2020","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.cll.2026.02.011_bib30","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1160\/TH06-10-0607","article-title":"Monitoring direct thrombin inhibitors with a plasma diluted thrombin time","volume":"98","author":"Love","year":"2007","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1016\/j.cll.2026.02.011_bib31","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1345\/aph.1D565","article-title":"Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing","volume":"38","author":"Gosselin","year":"2004","journal-title":"Ann Pharmacother"},{"issue":"10","key":"10.1016\/j.cll.2026.02.011_bib32","doi-asserted-by":"crossref","first-page":"e465","DOI":"10.1097\/PCC.0000000000003003","article-title":"Bivalirudin or unfractionated heparin for anticoagulation in pediatric patients on continuous flow ventricular assist device support: single-center retrospective cohort study","volume":"23","author":"Puri","year":"2022","journal-title":"Pediatr Crit Care Med"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib33","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11239-019-01961-3","article-title":"Evaluation of intravenous direct thrombin inhibitor monitoring tests: correlation with plasma concentrations and clinical outcomes in hospitalized patients","volume":"49","author":"Beyer","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"10.1016\/j.cll.2026.02.011_bib34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1309\/AJCPGTCEX7K4GXQO","article-title":"Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples","volume":"141","author":"Lind","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.02.011_bib35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqac131","article-title":"Monitoring direct thrombin inhibitors with calibrated diluted thrombin time vs activated partial thromboplastin time in pediatric patients","volume":"159","author":"Hasan","year":"2023","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib36","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1093\/jalm\/jfad072","article-title":"Chromogenic and clot-based bivalirudin assays for monitoring anticoagulation","volume":"8","author":"Raghavendran","year":"2023","journal-title":"J Appl Lab Med"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1055\/s-0038-1649637","article-title":"A quantitative thrombin time for determining levels of hirudin and hirulog","volume":"70","author":"Reid","year":"1993","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib38","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ijlh.13780","article-title":"How to best monitor bivalirudin anticoagulant effect for ECMO and VAD \u2013 Comparison of four assay methods","volume":"44","author":"Teruya","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"7","key":"10.1016\/j.cll.2026.02.011_bib39","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1097\/PCC.0000000000003527","article-title":"Bivalirudin monitoring in pediatric ventricular assist device and extracorporeal membrane oxygenation: analysis of single-center retrospective cohort data 2018-2022","volume":"25","author":"Engel","year":"2024","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"10.1016\/j.cll.2026.02.011_bib40","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/jth.13539","article-title":"Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study","volume":"15","author":"Hanslik","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"7","key":"10.1016\/j.cll.2026.02.011_bib41","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/jth.14806","article-title":"Anti-factor IIa (FIIa) heparin assay for patients on direct factor Xa (FXa) inhibitors","volume":"18","author":"Stuart","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.011_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2025.111836","article-title":"Preliminary insights into monitoring bivalirudin anticoagulation: a retrospective cohort study of aPTT versus a chromogenic anti-IIa assay","volume":"103","author":"Yates","year":"2025","journal-title":"J Clin Anesth"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib43","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1309\/Q0G21Y26UR0UHQ1A","article-title":"Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors","volume":"130","author":"Calatzis","year":"2008","journal-title":"Am J Clin Pathol"},{"issue":"7","key":"10.1016\/j.cll.2026.02.011_bib44","first-page":"1027","article-title":"Prothrombinase-induced clotting time to measure drug concentrations of rivaroxaban, apixaban, and edoxaban in clinical practice: a cross-sectional study","volume":"12","author":"Sathanantham","year":"2022","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1016\/j.cll.2026.02.011_bib45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/phar.2776","article-title":"Correlation between partial thromboplastin time and thromboelastography in adult critically ill patients requiring bivalirudin for extracorporeal membrane oxygenation","volume":"43","author":"Buckley","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"7","key":"10.1016\/j.cll.2026.02.011_bib46","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/ajh.25852","article-title":"Ecarin based coagulation testing","volume":"95","author":"Gosselin","year":"2020","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.cll.2026.02.011_bib47","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/S0002-9149(03)00159-0","article-title":"Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations","volume":"91","author":"Cho","year":"2003","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2004.02.012","article-title":"Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration","volume":"113","author":"Casserly","year":"2004","journal-title":"Thromb Res"},{"issue":"5","key":"10.1016\/j.cll.2026.02.011_bib49","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1213\/01.ane.0000205746.50440.98","article-title":"Measurement of patients\u2019 bivalirudin plasma levels by a thrombelastograph ecarin clotting time assay: a comparison to a standard activated clotting time","volume":"102","author":"Carroll","year":"2006","journal-title":"Anesth Analg"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1540-8191.2008.00604.x","article-title":"Monitoring of bivalirudin anticoagulation during and after cardiopulmonary bypass using an ecarin-activated TEG system","volume":"23","author":"Koster","year":"2008","journal-title":"J Card Surg"},{"key":"10.1016\/j.cll.2026.02.011_bib51","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.thromres.2023.05.022","article-title":"Use of ecarin chromogenic assay during bivalirudin anticoagulation in adult extracorporeal membrane oxygenation","volume":"228","author":"Krauter","year":"2023","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.cll.2026.02.011_bib52","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1053\/j.jvca.2019.08.022","article-title":"Role of bivalirudin for anticoagulation in adult perioperative cardiothoracic practice","volume":"34","author":"Erdoes","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"8","key":"10.1016\/j.cll.2026.02.011_bib53","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1053\/j.jvca.2020.01.020","article-title":"The use of bivalirudin in pediatric cardiac surgery and in the interventional cardiology suite","volume":"34","author":"Goswami","year":"2020","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib54","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1053\/j.jvca.2018.04.028","article-title":"Randomized controlled trial of heparin versus bivalirudin anticoagulation in acyanotic children undergoing open heart surgery","volume":"32","author":"Hasija","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"10","key":"10.1016\/j.cll.2026.02.011_bib55","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1053\/j.jvca.2022.04.044","article-title":"Bivalirudin anticoagulation in neonates and infants undergoing cardiac surgery","volume":"36","author":"Hasija","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"12","key":"10.1016\/j.cll.2026.02.011_bib56","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/jth.15538","article-title":"Clinical use of thrombin generation assays","volume":"19","author":"Binder","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.cll.2026.02.011_bib57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.thromres.2020.05.020","article-title":"Age-specific differences in the in vitro anticoagulant effect of bivalirudin in healthy neonates and children compared to adults","volume":"192","author":"Letunica","year":"2020","journal-title":"Thromb Res"},{"issue":"Suppl.1","key":"10.1016\/j.cll.2026.02.011_bib58","first-page":"90","article-title":"The utility of thrombin generation assay for bivalirudin monitoring in pediatric extracorporeal life support","volume":"45","author":"Kostousov","year":"2023","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"10.1016\/j.cll.2026.02.011_bib59","article-title":"A new test for the detection of direct oral anticoagulants (rivaroxaban and apixaban) in the emergency room setting","volume":"1","author":"Frydman","year":"2019","journal-title":"Crit Care Explor"},{"issue":"10","key":"10.1016\/j.cll.2026.02.011_bib60","article-title":"Novel coagulation test detects anticoagulation resistance and is associated with thrombotic events in pediatric patients requiring extracorporeal membrane oxygenation","volume":"4","author":"Frydman","year":"2022","journal-title":"Crit Care Explor"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib61","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2125.2011.03916.x","article-title":"Direct thrombin inhibitors","volume":"72","author":"Lee","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib63","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1023\/A:1012919404290","article-title":"A synopsis of the clinical uses of argatroban","volume":"12","author":"Moledina","year":"2001","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/ijlh.13757","article-title":"Laboratory methods for monitoring argatroban in heparin-induced thrombocytopenia","volume":"44","author":"Guy","year":"2022","journal-title":"Int J Lab Hematol"},{"issue":"7\u20138","key":"10.1016\/j.cll.2026.02.011_bib65","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1345\/aph.1R745","article-title":"Apparent argatroban resistance in a patient with elevated factor VIII levels","volume":"47","author":"Kennedy","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/0897190019885232","article-title":"Early identification of argatroban resistance and the consideration of factor VIII","volume":"34","author":"Poyant","year":"2019","journal-title":"J Pharm Pract"},{"issue":"9","key":"10.1016\/j.cll.2026.02.011_bib67","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1053\/j.jvca.2024.04.006","article-title":"Impact of C-reactive protein on anticoagulation monitoring in extracorporeal membrane oxygenation","volume":"38","author":"Madhok","year":"2024","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib68","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/0018578720946765","article-title":"Monitoring and dosing of argatroban in a patient with antiphospholipid syndrome","volume":"56","author":"Dooling","year":"2021","journal-title":"Hosp Pharm"},{"issue":"5","key":"10.1016\/j.cll.2026.02.011_bib69","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/ijlh.14488","article-title":"Variability of argatroban effects on the multiple APTT reagents in high and low coagulation activity samples","volume":"47","author":"Kumano","year":"2025","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib70","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/ijlh.12414","article-title":"Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban","volume":"37","author":"Guy","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib71","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1055\/s-0037-1603356","article-title":"More on the limitations of the activated partial thromboplastin time for monitoring argatroban therapy","volume":"43","author":"Guy","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.cll.2026.02.011_bib72","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s13054-015-1109-0","article-title":"Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial","volume":"19","author":"Tardy-Poncet","year":"2015","journal-title":"Crit Care"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib73","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/bjh.18120","article-title":"Managing argatroban in heparin-induced thrombocytopenia: a retrospective analysis of 729 treatment days in 32 patients with confirmed heparin-induced thrombocytopenia","volume":"197","author":"Marchetti","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib74","first-page":"1180","article-title":"Monitoring anticoagulation with argatroban in critically ill patients: activated partial thromboplastin time versus diluted thrombin time","volume":"116","author":"Keyl","year":"2016","journal-title":"Thromb Haemost"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib75","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1076029617699087","article-title":"Monitoring of argatroban and lepirudin: what is the input of laboratory values in \u201creal life\u201d?","volume":"24","author":"Seidel","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"6","key":"10.1016\/j.cll.2026.02.011_bib76","doi-asserted-by":"crossref","first-page":"E303","DOI":"10.1002\/ajh.24344","article-title":"Argatroban monitoring: aPTT versus chromogenic assay","volume":"91","author":"Vu","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cll.2026.02.011_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251341315","article-title":"Activated partial thromboplastin time and anti-IIa monitoring in argatroban anticoagulation in COVID-19 patients on venovenous extracorporeal membrane oxygenation","volume":"31","author":"Bur\u0161a","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.cll.2026.02.011_bib78","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12871-018-0475-y","article-title":"Monitoring of argatroban and lepirudin anticoagulation in critically ill patients by conventional laboratory parameters and rotational thromboelastometry \u2013 a prospectively controlled randomized double-blind clinical trial","volume":"18","author":"Beiderlinden","year":"2018","journal-title":"BMC Anesthesiol"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib79","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/ALN.0000000000004787","article-title":"Monitoring of argatroban in critically ill patients: a prospective study comparing activated partial thromboplastin time, point-of-care viscoelastic testing with ecarin clotting time and diluted thrombin time to mass spectrometry","volume":"140","author":"Heubner","year":"2024","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.cll.2026.02.011_bib80","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1055\/a-2000-6576","article-title":"In vitro effect of dalteparin and argatroban on hemostasis in critically ill sepsis patients with new-onset thrombocytopenia","volume":"7","author":"Nygaard","year":"2023","journal-title":"TH Open"},{"issue":"2","key":"10.1016\/j.cll.2026.02.011_bib81","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0609.2006.00786.x","article-title":"Argatroban for anticoagulation during cardiac surgery","volume":"78","author":"Martin","year":"2007","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.cll.2026.02.011_bib82","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1510\/icvts.2009.215848","article-title":"Argatroban as a substitute of heparin during cardiopulmonary bypass: a safe alternative?","volume":"10","author":"Follis","year":"2010","journal-title":"Interact Cardiovasc Thorac Surg"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:02:47Z","timestamp":1783620167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":81,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0272271226000119"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.011","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updates on Use and Monitoring of Direct Thrombin Inhibitors","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}